Tom Hanks continues donating plasma to Covid-19 patients

Plasma derived from people like Hanks, who have successfully recovered from the virus, may contain antibodies


Entertainment Desk May 28, 2020
Actor Tom Hanks took to Instagram on Wednesday to share photos of donating convalescent plasma to help in the fight against Covid-19, according to CNN.

Plasma derived from blood in people, like Hanks, who have successfully recovered from the virus, may contain antibodies that can potentially help people fighting the illness.

Hanks captioned the photo saying, "Plasmatic on 3! 1,2,3 PLASMATIC! Hanx."

https://www.instagram.com/p/CAswDV6JBd3/?utm_source=ig_embed

Last month the actor shared a similar photo, following what appeared to be his first time donating plasma. His wife, Rita Wilson, and him were hospitalized in Queensland, Australia in early March after being diagnosed with the novel coronavirus.

In an interview with NPR last month, Hanks said that the couple hoped their plasma could be beneficial in Covid-19 treatment.

https://www.instagram.com/p/B_kpLiipcO1/?utm_source=ig_embed

"Rita went through a tougher time than I did," Hanks said about their experiences with the illness. "She had a much higher fever and she had some other symptoms. She lost her sense of taste and smell. She got absolutely no joy from food for a better part of three weeks ... She was so nauseous she had to crawl on the floor from the bed to the facilities."

https://www.instagram.com/p/B_k8kJQn1h3/?utm_source=ig_embed

Wilson spoke about the terrible symptoms including fever and chills she experienced as a result. She said, "I felt extremely achy, uncomfortable, didn't want to be touched, and then the fever started," Wilson told Gayle King. She also discussed having a temperature of 102 degrees Fahrenheit and "chills like I never had before."

Have something to add to the story? Share it in the comments below.

COMMENTS

Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ